Innate Pharma Ownership 2024 | Who Owns Innate Pharma Now?
Institutional Ownership
0.32%
Institutional Holders
9.00
Innate Pharma Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| EXCHANGE TRADED CONCEPTS, LLC | 0.14% | 0.01% | 113,070 | 66,182 | 141.15% | 325,642 | Mar 31, 2024 |
| OPTIVER HOLDING B.V. | 0.09% | 0.00% | 70,564 | 47,859 | 210.79% | 203,224 | Mar 31, 2024 |
| MORGAN STANLEY | 0.05% | - | 44,124 | -2,230 | -4.81% | 127,077 | Mar 31, 2024 |
| JANE STREET GROUP, LLC | 0.02% | - | 14,554 | 14,554 | 100.00% | 41,916 | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.01% | - | 10,579 | -1,423 | -11.86% | 30,468 | Mar 31, 2024 |
| BARCLAYS PLC | 0.00% | - | 412 | - | - | 1,000 | Mar 31, 2024 |
| UBS GROUP AG | 0.00% | - | 210 | 64 | 43.84% | 604 | Mar 31, 2024 |
| RHUMBLINE ADVISERS | 0.00% | - | 205 | - | - | 590,000 | Mar 31, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 0.00% | - | 200 | - | - | 576 | Mar 31, 2024 |
Innate Pharma's largest institutional shareholder is EXCHANGE TRADED CONCEPTS, LLC, holding 0.14% of the company's total share outstanding, currently valued at $325.64K. The top 10 institutional shareholders own together 0.32% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| EXCHANGE TRADED CONCEPTS, LLC | 0.14% | 0.01% | 113,070 | 66,182 | 141.15% | 325,642 | Mar 31, 2024 |
| OPTIVER HOLDING B.V. | 0.09% | 0.00% | 70,564 | 47,859 | 210.79% | 203,224 | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.01% | - | 10,579 | -1,423 | -11.86% | 30,468 | Mar 31, 2024 |
| MORGAN STANLEY | 0.05% | - | 44,124 | -2,230 | -4.81% | 127,077 | Mar 31, 2024 |
| JANE STREET GROUP, LLC | 0.02% | - | 14,554 | 14,554 | 100.00% | 41,916 | Mar 31, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 0.00% | - | 200 | - | - | 576 | Mar 31, 2024 |
| RHUMBLINE ADVISERS | 0.00% | - | 205 | - | - | 590,000 | Mar 31, 2024 |
| BARCLAYS PLC | 0.00% | - | 412 | - | - | 1,000 | Mar 31, 2024 |
| UBS GROUP AG | 0.00% | - | 210 | 64 | 43.84% | 604 | Mar 31, 2024 |
The largest Innate Pharma shareholder by % of total assets is EXCHANGE TRADED CONCEPTS, LLC. The company owns 113.07K shares of Innate Pharma (IPHA), representing 0.01% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| EXCHANGE TRADED CONCEPTS, LLC | 0.14% | 0.01% | 113,070 | 66,182 | 141.15% | 325,642 | Mar 31, 2024 |
| OPTIVER HOLDING B.V. | 0.09% | 0.00% | 70,564 | 47,859 | 210.79% | 203,224 | Mar 31, 2024 |
| JANE STREET GROUP, LLC | 0.02% | - | 14,554 | 14,554 | 100.00% | 41,916 | Mar 31, 2024 |
| UBS GROUP AG | 0.00% | - | 210 | 64 | 43.84% | 604 | Mar 31, 2024 |
| BARCLAYS PLC | 0.00% | - | 412 | - | - | 1,000 | Mar 31, 2024 |
| RHUMBLINE ADVISERS | 0.00% | - | 205 | - | - | 590,000 | Mar 31, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 0.00% | - | 200 | - | - | 576 | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.01% | - | 10,579 | -1,423 | -11.86% | 30,468 | Mar 31, 2024 |
| MORGAN STANLEY | 0.05% | - | 44,124 | -2,230 | -4.81% | 127,077 | Mar 31, 2024 |
As of Mar 31 2024, Innate Pharma's largest institutional buyer is EXCHANGE TRADED CONCEPTS, LLC. The company purchased 66.18K stocks of IPHA, valued at $325.64K.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| MORGAN STANLEY | 0.05% | - | 44,124 | -2,230 | -4.81% | 127,077 | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.01% | - | 10,579 | -1,423 | -11.86% | 30,468 | Mar 31, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 0.00% | - | 200 | - | - | 576 | Mar 31, 2024 |
| RHUMBLINE ADVISERS | 0.00% | - | 205 | - | - | 590,000 | Mar 31, 2024 |
| BARCLAYS PLC | 0.00% | - | 412 | - | - | 1,000 | Mar 31, 2024 |
| UBS GROUP AG | 0.00% | - | 210 | 64 | 43.84% | 604 | Mar 31, 2024 |
| JANE STREET GROUP, LLC | 0.02% | - | 14,554 | 14,554 | 100.00% | 41,916 | Mar 31, 2024 |
| OPTIVER HOLDING B.V. | 0.09% | 0.00% | 70,564 | 47,859 | 210.79% | 203,224 | Mar 31, 2024 |
| EXCHANGE TRADED CONCEPTS, LLC | 0.14% | 0.01% | 113,070 | 66,182 | 141.15% | 325,642 | Mar 31, 2024 |
As of Mar 31 2024, Innate Pharma's biggest institutional seller is MORGAN STANLEY. The company sold -2.23K shares of IPHA, valued at $127.08K.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| JANE STREET GROUP, LLC | 0.02% | - | 14,554 | 14,554 | 100.00% | 41,916 | Mar 31, 2024 |
Innate Pharma's largest new institutional shareholder by number of shares is JANE STREET GROUP, LLC, purchased 14.55K shares, valued at $41.92K, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|
Innate Pharma Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| ALPS ETF Trust | 0.01% | 79,097 | - | - | Feb 29, 2024 |
| ETF Series Solutions | 0.00% | 55,168 | 8,842 | 19.09% | Feb 29, 2024 |
| TRUST FOR PROFESSIONAL MANAGERS | 0.00% | 22,465 | 14,838 | 194.55% | Feb 29, 2024 |
| iSHARES TRUST | 0.00% | 486,495 | - | - | Feb 29, 2024 |
Innate Pharma's largest mutual fund holder by % of total assets is "ALPS ETF Trust", owning 79.10K shares, compromising 0.01% of its total assets.
Innate Pharma Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 31 Mar, 24 | 9 | 12.50% |
| 31 Dec, 23 | 8 | - |
| 30 Sep, 23 | 8 | -11.11% |
| 30 Jun, 23 | 9 | 28.57% |
| 31 Mar, 23 | 7 | -22.22% |
| 31 Dec, 22 | 9 | - |
| 30 Sep, 22 | 9 | -25.00% |
| 30 Jun, 22 | 12 | - |
| 31 Mar, 22 | 12 | -20.00% |
| 31 Dec, 21 | 15 | -16.67% |
| 30 Sep, 21 | 18 | - |
| 31 Mar, 21 | 7 | 75.00% |
| 31 Dec, 20 | 4 | -33.33% |
| 30 Sep, 20 | 6 | -14.29% |
| 30 Jun, 20 | 7 | -30.00% |
| 31 Mar, 20 | 10 | -16.67% |
| 31 Dec, 19 | 12 | - |
As of 31 Mar 24, 9 institutions are holding Innate Pharma's shares, representing an increase of 12.50% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 31 Mar, 24 | 253,918 | 96.97% |
| 31 Dec, 23 | 128,912 | -59.51% |
| 30 Sep, 23 | 318,407 | 35.34% |
| 30 Jun, 23 | 235,270 | -38.67% |
| 31 Mar, 23 | 383,638 | -0.73% |
| 31 Dec, 22 | 386,442 | -59.07% |
| 30 Sep, 22 | 944,107 | -1.07% |
| 30 Jun, 22 | 954,312 | 0.22% |
| 31 Mar, 22 | 952,242 | -31.50% |
| 31 Dec, 21 | 1,390,120 | 47.40% |
| 30 Sep, 21 | 943,114 | - |
| 31 Mar, 21 | 176,028 | -87.39% |
| 31 Dec, 20 | 1,395,579 | -17.12% |
| 30 Sep, 20 | 1,683,925 | -41.36% |
| 30 Jun, 20 | 2,871,409 | -60.88% |
| 31 Mar, 20 | 7,340,005 | -4.86% |
| 31 Dec, 19 | 7,714,580 | - |
Innate Pharma (IPHA) has 253.92K shares outstanding as of 31 Mar 24, up 96.97% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 31 Mar, 24 | 0.32% | 1204.32% |
| 31 Dec, 23 | 0.16% | 101.28% |
| 30 Sep, 23 | 0.40% | 458.16% |
| 30 Jun, 23 | 0.30% | 127.32% |
| 31 Mar, 23 | 0.48% | 204.60% |
| 31 Dec, 22 | 0.49% | 34.53% |
| 30 Sep, 22 | 1.19% | 82.36% |
| 30 Jun, 22 | 1.20% | 83.72% |
| 31 Mar, 22 | 1.20% | 39.20% |
| 31 Dec, 21 | 1.75% | 124.31% |
| 30 Sep, 21 | 1.19% | - |
| 31 Mar, 21 | 0.22% | 7.13% |
| 31 Dec, 20 | 1.77% | 42.25% |
| 30 Sep, 20 | 2.05% | 16.81% |
| 30 Jun, 20 | 3.49% | 2.90% |
| 31 Mar, 20 | 10.97% | 8.25% |
| 31 Dec, 19 | 11.53% | - |
As of 31 Mar 24, Innate Pharma is held by 0.32% institutional shareholders, representing a 1204.32% growth compared to 31 Dec 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 4 | 100.00% |
| 31 Dec, 23 | 2 | 100.00% |
| 30 Sep, 23 | 1 | -66.67% |
| 30 Jun, 23 | 3 | 50.00% |
| 31 Mar, 23 | 2 | -50.00% |
| 31 Dec, 22 | 4 | - |
| 30 Sep, 22 | 4 | -33.33% |
| 30 Jun, 22 | 6 | 20.00% |
| 31 Mar, 22 | 5 | -44.44% |
| 31 Dec, 21 | 9 | -50.00% |
| 30 Sep, 21 | 18 | - |
| 31 Mar, 21 | 5 | 400.00% |
| 31 Dec, 20 | 1 | - |
| 30 Sep, 20 | 1 | -50.00% |
| 30 Jun, 20 | 2 | -50.00% |
| 31 Mar, 20 | 4 | -66.67% |
| 31 Dec, 19 | 12 | - |
4 institutional shareholders have increased their position in IPHA stock as of 31 Mar 24 compared to 2 in the previous quarter (a 100.00% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 2 | -33.33% |
| 31 Dec, 23 | 3 | - |
| 30 Sep, 23 | 3 | -25.00% |
| 30 Jun, 23 | 4 | 33.33% |
| 31 Mar, 23 | 3 | -25.00% |
| 31 Dec, 22 | 4 | - |
| 30 Sep, 22 | 4 | - |
| 30 Jun, 22 | 4 | -20.00% |
| 31 Mar, 22 | 5 | - |
| 31 Dec, 21 | 5 | - |
| 30 Sep, 21 | - | - |
| 31 Mar, 21 | 2 | - |
| 31 Dec, 20 | 2 | - |
| 30 Sep, 20 | 2 | - |
| 30 Jun, 20 | - | -100.00% |
| 31 Mar, 20 | 5 | - |
| 31 Dec, 19 | - | - |
2 institutional shareholders have reduced their position in IPHA stock as of 31 Mar 24 compared to 3 in the previous quarter (a -33.33% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar, 24 | 9 | 12.50% | 253,918 | 96.97% | 0.32% | 1204.32% | 4 | 100.00% | 2 | -33.33% |
| 31 Dec, 23 | 8 | - | 128,912 | -59.51% | 0.16% | 101.28% | 2 | 100.00% | 3 | - |
| 30 Sep, 23 | 8 | -11.11% | 318,407 | 35.34% | 0.40% | 458.16% | 1 | -66.67% | 3 | -25.00% |
| 30 Jun, 23 | 9 | 28.57% | 235,270 | -38.67% | 0.30% | 127.32% | 3 | 50.00% | 4 | 33.33% |
| 31 Mar, 23 | 7 | -22.22% | 383,638 | -0.73% | 0.48% | 204.60% | 2 | -50.00% | 3 | -25.00% |
| 31 Dec, 22 | 9 | - | 386,442 | -59.07% | 0.49% | 34.53% | 4 | - | 4 | - |
| 30 Sep, 22 | 9 | -25.00% | 944,107 | -1.07% | 1.19% | 82.36% | 4 | -33.33% | 4 | - |
| 30 Jun, 22 | 12 | - | 954,312 | 0.22% | 1.20% | 83.72% | 6 | 20.00% | 4 | -20.00% |
| 31 Mar, 22 | 12 | -20.00% | 952,242 | -31.50% | 1.20% | 39.20% | 5 | -44.44% | 5 | - |
| 31 Dec, 21 | 15 | -16.67% | 1,390,120 | 47.40% | 1.75% | 124.31% | 9 | -50.00% | 5 | - |
| 30 Sep, 21 | 18 | - | 943,114 | - | 1.19% | - | 18 | - | - | - |
| 31 Mar, 21 | 7 | 75.00% | 176,028 | -87.39% | 0.22% | 7.13% | 5 | 400.00% | 2 | - |
| 31 Dec, 20 | 4 | -33.33% | 1,395,579 | -17.12% | 1.77% | 42.25% | 1 | - | 2 | - |
| 30 Sep, 20 | 6 | -14.29% | 1,683,925 | -41.36% | 2.05% | 16.81% | 1 | -50.00% | 2 | - |
| 30 Jun, 20 | 7 | -30.00% | 2,871,409 | -60.88% | 3.49% | 2.90% | 2 | -50.00% | - | -100.00% |
| 31 Mar, 20 | 10 | -16.67% | 7,340,005 | -4.86% | 10.97% | 8.25% | 4 | -66.67% | 5 | - |
| 31 Dec, 19 | 12 | - | 7,714,580 | - | 11.53% | - | 12 | - | - | - |
Innate Pharma Peer Ownership
| Ticker | Company |
|---|---|
| ANEB | Anebulo Pharmaceuticals, Inc. |
| CYT | Cyteir Therapeutics, Inc. |
| ELYM | Eliem Therapeutics, Inc. |
| HCWB | HCW Biologics Inc. |
| INBX | Inhibrx, Inc. |
| IPSC | Century Therapeutics, Inc. |
| CSBR | Champions Oncology, Inc. |
| STTK | Shattuck Labs, Inc. |
| DYAI | Dyadic International, Inc. |
| ADXN | Addex Therapeutics Ltd |
| MOLN | Molecular Partners AG |
| MNOV | MediciNova, Inc. |
| PRDS | Pardes Biosciences, Inc. |
IPHA Ownership FAQ
Who Owns Innate Pharma?
Innate Pharma is owned by institutional shareholders (0.32%), insiders (0.00%), and public (99.68%). The largest institutional shareholder of Innate Pharma is EXCHANGE TRADED CONCEPTS, LLC (0.14% of total shares) and the top mutual fund owner is ALPS ETF Trust (0.01% of total shares).
Who are the major institutional shareholders of Innate Pharma?
Innate Pharma's major institutional shareholders are EXCHANGE TRADED CONCEPTS, LLC, OPTIVER HOLDING B.V., MORGAN STANLEY, JANE STREET GROUP, LLC, and MILLENNIUM MANAGEMENT LLC. The top five shareholders own together 0.31% of the company's share outstanding.
How many Innate Pharma shareholders are there?
As of Mar 2024, there are 9 institutional shareholders of Innate Pharma.
What percentage of Innate Pharma is owned by EXCHANGE TRADED CONCEPTS, LLC?
EXCHANGE TRADED CONCEPTS, LLC owns 113.07K shares of Innate Pharma, representing 0.14% of the company's total shares outstanding, valued at $325.64K (as of Mar 2024).
What percentage of Innate Pharma is owned by OPTIVER HOLDING B.V?
As of Mar 2024, OPTIVER HOLDING B.V holds 70.56K shares of Innate Pharma (IPHA), compromising 0.09% of the company, valued at $203.22K.
What percentage of Innate Pharma is owned by MORGAN STANLEY?
MORGAN STANLEY is the third largest holder of Innate Pharma. The company owns 44.12K of the company's shares outstanding (worth $127.08K).